MarketCapExport financials
OPKO Health (OPK)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
OPKO Health Income Statement 2025-2008 | OPK
Brief overview of financial performance at OPKO Health
The conclusions below are based on five years of reported results. According to figures from OPKO Health, revenue changed from 902 million dollars to 184 million dollars over five years. The total change was −79.6%, with a CAGR of approximately −27.3%. The decline points to a contraction in the scale of the business.
The five-year change in gross profit reached −33.7%: from $329 million to $219 million. At the margin level, the figure shifted from 36.5% to 119%. A wider margin shows that the economics of the core business improved.
EBITDA was −132 million dollars at the beginning and −53.9 million dollars at the end of the period (+59.1%). The operating result outpaced sales and points to improving efficiency. EBITDA margin was −14.6% at the start and −29.3% at the end. Cost pressure reduced operating profitability.
Across the five years, the net result shifted from −315 million dollars to 14 million dollars. The trajectory reversed from a loss to positive earnings.
The five-year change in capitalization reached +37.8%: from 881 million dollars to 1.2 billion dollars. Market value lagged the financial performance.
Financial takeaway
Signs of deterioration dominate the five-year picture. The strongest signals are a stronger gross margin and improving net profitability. The weaker side of the profile includes a softer top-line trend, a low EBITDA margin and pressure on operating profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.
Annual Income Statement OPKO Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
1.04 B | 1.21 B | 744 M | 820 M | 2.03 B | 3.47 B | 881 M | 2.11 B | 2.57 B | 4.26 B | 4.02 B | 5.08 B | 2.89 B | 1.91 B | 1.46 B | 503 M | - | - |
Shares |
751 M | 694 M | 752 M | 719 M | 648 M | 641 M | 595 M | 567 M | 559 M | 502 M | 500 M | 419 M | 355 M | 296 M | 281 M | 255 M | - | - |
Historical Prices |
1.38 | 1.75 | 0.99 | 1.14 | 3.13 | 5.41 | 1.45 | 3.68 | 4.46 | 8.69 | 8.04 | 12.1 | 7.93 | 6.42 | 5.26 | 1.97 | 1.2 | 2.3 |
Net Income |
-226 B | -53.2 B | -189 B | -328 B | -30.1 M | 30.6 M | -315 M | -153 M | -309 M | -25.1 M | -30 M | -172 M | -114 M | -29 M | -1.28 M | -18.9 M | -30.1 M | - |
Revenue |
148 M | 184 M | 863 M | 1 B | 1.77 B | 1.44 B | 902 M | 990 M | 1.07 B | 1.22 B | 492 M | 91.1 M | 96.5 M | 47 M | 28 M | - | - | - |
Cost of Revenue |
401 M | 495 M | 545 M | 716 M | - | - | - | - | - | 564 M | 193 M | 48 M | 48.9 M | 27.9 M | 17.2 M | 13.5 M | 2.88 M | - |
Gross Profit |
206 M | 219 M | 318 M | 288 M | - | - | 329 M | 386 M | 447 M | 610 M | 256 M | 43.1 M | 47.7 M | 19.2 M | 10.7 M | 15 M | 1.54 M | - |
Operating Income |
-117 M | -152 M | -157 M | -226 M | 18.8 M | 57.7 M | -274 M | -171 M | -276 M | -96.6 M | -121 M | -146 M | -79.6 M | -37.3 M | -23.2 M | -11.1 M | -22.1 M | - |
Interest Expense |
- | 207 M | 13.5 M | 12.1 M | 18.9 M | 12.7 M | -11.3 M | 1.54 M | 10.5 M | 3.9 M | 7.73 M | -3.09 M | 34.8 M | 164 K | 1 M | 1.22 M | 1.76 M | - |
EBITDA |
-25.8 M | -53.9 M | -51.7 M | -118 M | 97.5 M | 143 M | -132 M | -98.3 M | -199 M | 8.09 M | -65.5 M | -98.4 M | -61.6 M | -28.1 M | -19.8 M | -8.93 M | -21.6 M | - |
Operating Expenses |
187 M | 217 M | 251 M | 241 M | 1.76 B | 1.38 B | 526 M | 552 M | 731 M | 666 M | 350 M | 152 M | 120 M | 55.6 M | 33.9 M | 26.1 M | 23.7 M | - |
General and Administrative Expenses |
223 M | 304 M | 301 M | 373 M | 469 M | 356 M | - | - | - | - | - | - | - | - | - | 18.1 M | 10.4 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement OPKO Health
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
746 M | 755 M | 759 M | 5 M | 777 M | 788 M | 672 M | -5.66 M | 695 M | 697 M | 707 M | - | 752 M | 752 M | 752 M | - | 750 M | 713 M | 660 M | - | 652 M | 647 M | 641 M | - | 641 M | 641 M | 641 M | - | 586 M | 586 M | 586 M | - | 560 M | 560 M | 559 M | - | 559 M | 559 M | 558 M | - | 552 M | 548 M | 546 M | - | 501 M | 462 M | 446 M | 3.36 M | 428 M | 413 M | 413 M | - | 361 M | 337 M | 313 M | 298 M | 298 M | - | - | 298 M | - | 288 M | - |
Net Income |
-53.5 M | -8.42 M | -54.8 M | -31.3 M | 21.6 M | -148 M | -67.6 M | 14 M | 24.9 M | -10.3 M | -81.8 M | -66.5 M | -84.5 M | -19.6 M | -18.3 M | -85.2 M | -86.1 M | -102 M | -55.4 M | -73.8 M | 28.7 M | -16.2 M | 31.1 M | 32.3 M | 23.7 M | 33.7 M | -59.1 M | -112 M | -62 M | -59.8 M | -80.8 M | -76.1 M | -27.7 M | -6.2 M | -43.1 M | -214 M | -35.9 M | -16.9 M | -34.5 M | -13.7 M | -15 M | 15.5 M | -12 M | 1.6 M | 128 M | -42.8 M | -117 M | -53 M | -48.7 M | -25.5 M | -44.5 M | -16.8 M | -60 M | -3.39 M | -34.2 M | -1.11 M | -9.65 M | -10.2 M | -8.61 M | 17.9 M | -8.24 M | -5.75 M | -5.7 M |
Revenue |
65.4 M | 164 M | 124 M | 148 M | 56.4 M | 157 M | 150 M | 184 M | 174 M | 182 M | 174 M | 182 M | 179 M | 265 M | 238 M | 185 M | 180 M | 310 M | 329 M | 401 M | 386 M | 442 M | 545 M | 495 M | 428 M | 301 M | 211 M | 224 M | 229 M | 226 M | 222 M | 222 M | 250 M | 264 M | 255 M | 161 M | 246 M | 293 M | 266 M | 247 M | 298 M | 357 M | 291 M | 276 M | 143 M | 42.4 M | 30.1 M | 25.5 M | 19.8 M | 23.5 M | 22.3 M | 20.7 M | 20.6 M | 23.8 M | 31.4 M | 16.3 M | 11.8 M | 10.2 M | 8.78 M | 5.79 M | 6.81 M | 8.43 M | 6.95 M |
Cost of Revenue |
23.4 M | 83.6 M | 78.4 M | 332 M | 21.4 M | 107 M | 107 M | 99 M | 134 M | 131 M | 132 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.4 M | 10.3 M | -26.7 M | 11.1 M | 12.6 M | 12.4 M | - | 12 M | 13.1 M | 11.8 M | - | 7.49 M | 6.55 M | 4.99 M | - | 4.02 M | 4.89 M | 4.18 M |
Gross Profit |
42.1 M | 80 M | 45.8 M | 116 M | 35.1 M | 49.4 M | 42.6 M | 84.7 M | 40.1 M | 51.7 M | 42.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28 M | 19.8 M | 52.2 M | 8.65 M | 11 M | 9.88 M | 56.6 M | 39.6 M | 41.8 M | 38.1 M | 26 M | 21.2 M | 19.6 M | 17.6 M | 1.64 M | 2.79 M | 3.54 M | 2.77 M |
Operating Income |
-31.4 M | -6.97 M | -51 M | 1.51 M | -33.6 M | -60 M | -67.2 M | -33.1 M | -67.2 M | -61.7 M | -71.5 M | - | -64.4 M | 7.02 M | -30.6 M | - | -87.8 M | -10.7 M | -72.4 M | - | 37.8 M | 5.57 M | 38.4 M | - | 21.9 M | 27.2 M | -40.8 M | - | -39 M | -47.3 M | -75.3 M | - | -33.5 M | -5.11 M | -42.6 M | - | -47.8 M | -25.8 M | -45.2 M | - | -23.6 M | 28.3 M | -27.5 M | - | -8.22 M | -25.4 M | -56.9 M | -32.5 M | -48.2 M | -34.9 M | -30.3 M | - | -19 M | -18 M | -6.77 M | -1.04 M | -9.65 M | -10.2 M | -8.61 M | 10.4 M | -5.8 M | -5.35 M | -4.75 M |
Interest Expense |
3.86 M | 1.8 M | -1.71 M | 2.06 M | 1.22 M | -35.5 M | 4.85 M | 78.1 M | 48.6 M | 58.9 M | 21.3 M | - | -11.6 M | -21.4 M | 3.39 M | - | 3.02 M | -73 M | -1.44 M | - | -3.36 M | -11.8 M | -927 K | - | 4.75 M | 18.2 M | -12.3 M | - | -15.5 M | -5.87 M | 977 K | - | -824 K | 8.58 M | 1.89 M | - | 597 K | -533 K | 3.04 M | - | -2.97 M | 5.97 M | 546 K | - | 17.5 M | 760 K | -1.51 M | -5.13 M | -2.76 M | 2.99 M | 1.68 M | - | 1.87 M | 8.03 M | 2.33 M | - | 55 K | -266 K | 351 K | - | -671 K | -129 K | 87 K |
EBITDA |
-15 M | 12 M | -32.1 M | 30.3 M | -17 M | -40.5 M | -47.3 M | -12.8 M | -46.7 M | -37.5 M | -45.7 M | - | -38.2 M | 33.4 M | -4.15 M | - | -59.8 M | 12.1 M | -44.6 M | - | 56.8 M | 26.1 M | 58.4 M | - | 43 M | 49.4 M | -18.7 M | - | -15.2 M | -23.6 M | -51.5 M | - | -9.54 M | 19.7 M | -17.9 M | - | -22.4 M | -280 K | -19.5 M | - | 2.21 M | 52.8 M | -5.32 M | - | 4.18 M | -22.2 M | -54.2 M | -29.8 M | -45.5 M | -32.1 M | -27.5 M | - | -15.2 M | -14.5 M | -3.34 M | -1.04 M | -6.98 M | -7.79 M | -6.28 M | 10.4 M | -4.76 M | -4.41 M | -3.88 M |
Operating Expenses |
73.5 M | 87 M | 96.8 M | 187 M | 104 M | 217 M | 217 M | 217 M | 159 M | 244 M | 245 M | 251 M | 243 M | 258 M | 268 M | 241 M | 268 M | 321 M | 402 M | 464 M | 348 M | 437 M | 507 M | 445 M | 406 M | 274 M | 252 M | 337 M | 268 M | 274 M | 298 M | 312 M | 283 M | 269 M | 298 M | 319 M | 294 M | 318 M | 312 M | 326 M | 300 M | 309 M | 300 M | 284 M | 151 M | 67.8 M | 87 M | 58 M | 68 M | 58.4 M | 52.6 M | 56.6 M | 39.6 M | 41.8 M | 38.1 M | 27 M | 21.2 M | 19.6 M | 12.6 M | -8.74 M | 8.59 M | 8.31 M | 6.91 M |
General and Administrative Expenses |
24.8 M | 52.9 M | 48.6 M | 153 M | 22.3 M | 59.6 M | 59.1 M | 67 M | 98.2 M | 68.8 M | 70.2 M | - | 72.2 M | 79.8 M | 75.6 M | - | 79.7 M | 101 M | 118 M | - | 105 M | 113 M | 112 M | - | 99.9 M | 77.7 M | 76.1 M | - | 80.5 M | 88.5 M | 95.2 M | - | 84.1 M | 87.7 M | 91.5 M | - | 103 M | 106 M | 110 M | - | 125 M | 118 M | 128 M | - | 55.2 M | 20.9 M | 17.4 M | 15.2 M | 14 M | 14.9 M | 13.8 M | - | 13.6 M | 13.9 M | 12.4 M | - | 7.32 M | 5.44 M | 4.67 M | - | 4.35 M | 4.7 M | 5.06 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company OPKO Health (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Waters Corporation
WAT
|
$ 476.29 | -0.09 % | $ 28.4 B |  USA |
 |
Exagen
XGN
|
$ 5.26 | -25.92 % | $ 113 M | USA |
 |
Celcuity
CELC
|
$ 67.13 | -4.11 % | $ 3.14 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 370.89 | -0.25 % | $ 30.9 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 101.65 | 0.63 % | $ 6.86 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
$ 664.97 | -1.18 % | $ 19.2 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 346.21 | -2.02 % | $ 17.2 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 750.2 | -0.69 % | $ 36.1 B |  Schweiz |
 |
Danaher Corporation
DHR
|
$ 236.19 | 0.46 % | $ 168 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 30.39 | -1.32 % | $ 28.8 B |  Niderland |
 |
RadNet
RDNT
|
$ 77.91 | -0.6 % | $ 5.86 B | USA |
 |
Senseonics Holdings
SENS
|
$ 10.05 | 2.55 % | $ 419 M | USA |
 |
Neuronetics
STIM
|
$ 2.01 | -7.8 % | $ 133 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 719.09 | -0.35 % | $ 271 B | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
$ 155.43 | -2.12 % | $ 19.5 B | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
$ 10.63 | -8.68 % | $ 361 M |  Israel |
 |
VolitionRx Limited
VNRX
|
$ 0.19 | -6.2 % | $ 23.9 M |  Singapore |
 |
Natera
NTRA
|
$ 311.81 | -1.92 % | $ 42.6 B | USA |
 |
IQVIA Holdings
IQV
|
$ 275.46 | -1.21 % | $ 47.4 B | USA |
 |
Agilent Technologies
A
|
$ 178.84 | -0.74 % | $ 50.8 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
DexCom
DXCM
|
$ 79.92 | -1.42 % | $ 31.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 258.38 | -0.5 % | $ 28.7 B | USA |
 |
Castle Biosciences
CSTL
|
$ 34.41 | 0.07 % | $ 997 M | USA |
 |
IDEXX Laboratories
IDXX
|
$ 696.77 | -1.4 % | $ 56 B | USA |
 |
Illumina
ILMN
|
$ 214.84 | -2.69 % | $ 33.3 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 3.05 | -3.48 % | $ 99 K | USA |
|
Biodesix
BDSX
|
$ 10.04 | -2.95 % | $ 75.8 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.25 | 7.66 % | $ 6.81 M | USA |
 |
Bioventus
BVS
|
$ 11.18 | 1.5 % | $ 745 M | USA |
 |
Fulgent Genetics
FLGT
|
$ 25.83 | -1.22 % | $ 795 M | USA |
 |
CareDx, Inc
CDNA
|
$ 80.78 | -4.31 % | $ 4.3 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | Britain |
 |
Biomerica
BMRA
|
$ 1.48 | -4.52 % | $ 4.31 M | USA |
 |
Interpace Biosciences
IDXG
|
$ 7.0 | -13.43 % | $ 31 M | USA |